Key points

In Infants

• Given that certain vaccines are required for entry into childcare settings, vaccination coverage is generally very high, with over 95% of children aged 24 months vaccinated against diphtheria, tetanus, polio, Haemophilus influenzae type b (Hib) infections, hepatitis B, and pneumococcal disease.
• Vaccination against invasive meningococcal disease (IMD) ACWY, mandatory since 2025 for infants in response to a rise in cases, warrants special attention: 88.2% of infants received a first dose of the ACWY meningococcal vaccine at 8 months, and 96.8% of infants received a first dose of the meningococcal B vaccine.
• Vaccination coverage against measles, mumps, and rubella at 24 months of age is 95.5% for the first dose, representing a very positive trend since 2018 (+4.6 percentage points). The resurgence of measles virus circulation in France since 2024 underscores the importance of achieving two-dose vaccination coverage exceeding 95%. This threshold is essential to prevent severe or fatal cases among vulnerable individuals (newborns, people undergoing cancer treatment, and post-transplant patients). However, the data show that this threshold is not being met for two-dose vaccination coverage, regardless of the source used.

Among adolescents

• Vaccination coverage for the human papillomavirus (HPV) vaccine continues to rise, particularly in the context of a vaccination policy focused on vaccination
  in middle schools. In 2025, 61.6% of 15-year-old girls had received a first dose of the vaccine, compared to 58.4% in 2024. Furthermore, 46.0% of 15-year-old boys had received a first dose of the vaccine, compared to 36.9% in 2024. The goal set by the 2021–2030 Ten-Year Cancer Control Strategy is to achieve 80% vaccination coverage by 2030, in order to eliminate cancers linked to HPV infections. Vaccination campaigns in middle schools will help achieve these goals (see summary of the middle school vaccination campaign for the 2024–2025 school year).
• In 2025, 17.1% of adolescents aged 11 to 14 were vaccinated against meningococcal ACWY; coverage is lower among young people aged 15 to 24 (7.9%). The inclusion of this vaccine in middle school campaigns starting in 2026 aims to strengthen protection for adolescents and young adults against potentially fatal IIMs, and also to indirectly protect other age groups, provided that vaccination coverage is high.

Vaccination uptake

Vaccine acceptance was reassessed in 2024 as part of the Santé publique France Public Health Barometer survey. The results show that vaccine acceptance remains high, with over 80% of adults aged 18 to 79 reporting a favorable view of vaccination. Higher acceptance is observed among young people and seniors, as well as among those who are socioeconomically better off. Among those opposed to vaccination, reluctance is concentrated primarily on the COVID-19 vaccine (25%), followed by the flu vaccine (7%).